## DERMATOLOGY REFERRAL FORM I-Z

## 877.RxHyVee (877.794.9833) 10004 S. 152nd Street, Suite C Omaha, NE 68138



| Patient Informa   | ation  | PLEASE FAX         | K INSUR   | RANCE CAI                                       | RD (  | FRONT AND BA      | CK)            |                                  | <b>Prescriber Information</b>           |             |                 |            |             |  |
|---|--|--------------------|---|---|-------|-------------------|----------------|----------------------------------|---|-------------|-----------------|------------|-------------|--|
| Last Name First Name  |  |                    |   |   | DOB   | DOB               |                |                                  | Practice/Facility Name                  |             |                 |            |             |  |
| Address   |  |                    |   |   |       |                   |                | Address                          |   |             |                 |            |             |  |
| City  |  |                    | ZIP   |   | 11    | City              | ate            | e ZIP                            |   |             |                 |            |             |  |
| Phone   |  |                    |   | SN  | •     |                   |                |                                  | Prescriber Name                         |             |                 |            |             |  |
| Allergies   | Latex Allergy Yes No   |                    |   |   |       | Prescriber NPI    |                |                                  |   |             |                 |            |             |  |
| Sex Male Female Weight (kg)   |  |                    | н   |   |       | Height (ft,in)    |                | ┧╽                               | Nurse/Key Contact                       |             | Phone/Pager     |            |             |  |
| Insurance Plan  | Plan ID #  |                    |   |   |       |                   | Fax En         | nail                             | ĺ                                       |             |                 |            |             |  |
| Diagnosis/Clini   | cal Info   | ormation           |   |   |       |                   |                |                                  |   |             |                 |            |             |  |
| Diagnosis: L20Atopic Dermatitis L40.0 Psoriasis vulgaris/Plaque psoriasis/Nummular psoriasis L40.8 Other psoriasis  L40.9 Psoriasis, unspecified L40.5 Psoriatic arthritis L73.2 Hidradenitis Suppurativa Other:  Date of diagnosis or years with the disease:  Active TB is ruled out: Yes No Date of negative TB test:/  Concomitant medications:  Previous treatment regimens with dates and reason for discontinuation: |  |                    |   |   |       |                   |                |                                  |   |             |                 |            |             |  |
| Prescription Information  |  |                    |   |   |       |                   |                |                                  |   |             |                 | DEFILLS    |             |  |
| MEDICATION  Remicade®   | Remicade <sup>®</sup> Weightkg   |                    | DOSE/STRENGTH/DIRECTIONS FOR USE  Starter dose: 5mg/kg (mg) IV at weeks                     |   |       |                   |                | _                                | 0.0 16                                  | +           | QTY<br>QS       |            | REFILLS     |  |
| Weightkg<br>Biosimilars:<br>Inflectra®  |  |                    |   |   |       | :: 5mg/kg(        |                | 56 day                           |   |             |                 |            |             |  |
| Siliq®  | PFS  |                    | Starter dose: Inject 210mg SC on weeks 0, 1 and 2, inject 210mg SC every 2 weeks thereafter |   |       |                   |                |                                  |   |             | 4 x 210mg/1.5ml |            | 0           |  |
|   |  |                    | Maintenance dose: Inject 210mg SC every 2 weeks   |   |       |                   |                |                                  |   |             | 2 x 210mg/1.5ml |            |             |  |
| Simponi®  | Smart<br>PFS   | Ject Autoinjector  | Inject 50mg SC once a month   |   |       |                   |                |                                  |   |             | 1 x 50mg/0.5ml  |            |             |  |
| Stelara®  | Stelara®   |                    |   | Starter dose: Inject 45mg SC on Day 1 (≤100 kg) |       |                   |                |                                  |   |             | 1 x 45mg/0.5ml  |            | 0           |  |
| Weightkg  | PFS  |                    | Starter dose: Inject 90mg SC on Day 1 (>100 kg)   |   |       |                   |                |                                  |   | 1 x 90mg/ml |                 |            |             |  |
|   |  |                    | Maintenance dose: Inject 45mg SC on Day 29 and  |   |       |                   |                |                                  | ,                                       |             | 1 x 45mg/0.5ml  |            |             |  |
|   |  |                    | Maintenance dose: Inject 90mg SC on Day 29 and every 12 weeks thereafter (>100 kg)          |   |       |                   |                |                                  |   |             | 1 x 90mg/ml     |            |             |  |
| Taltz® Autoinjector PFS   |  | injector           | Sta   | arter dose: I                                   | Injec | t 160mg (2 x 80m  | ıg) SC at weel | ), then inject 80mg SC at week 2 |   | 3 x 80mg    | /ml             | 0          |             |  |
|   | Autoinjector<br>PFS  |                    | Starter dose: Inject 80mg SC at week 4 and every 2  |   |       |                   |                | y 2                              | weeks thereafter through week 10        |             | 4 x 80mg/ml     |            | 0           |  |
|   | Autoinjector<br>PFS  |                    | Maintenance dose: Inject 80mg SC at week 12 an  |   |       |                   |                | nd                               | every 4 weeks thereafter                |             | 1 x 80mg/ml     |            |             |  |
| Tremfya®  | PFS  |                    | Starter dose: Inject 100mg SC at week 0, then 100mg at week 4 and every 8 weeks thereafter  |   |       |                   |                |                                  |   |             | 2 x 100mg/ml 0  |            | 0           |  |
|   |  |                    | Maintenance dose: Inject 100mg SC every 8 weeks   |   |       |                   |                |                                  |   |             | 1 x 100mg/ml    |            |             |  |
| Date needed:/_  | /  | Medication         | delivery  | to (choose                                      | one   | : Prescriber      | Home           | <u>,</u>                         | Other:                                  |             |                 |            |             |  |
| Injection training to be  | Injection training to be provided by: Prescriber's Office Hy-Vee Pharmacy Solutions Other: |                    |   |   |       |                   |                |                                  |   |             |                 |            |             |  |
| In order for a brand name substitution:   | product t  | to be dispensed, t | the preso   | criber must                                     | t han | dwrite "Brand Neo | cessary" or "B | 3ra                              | nd Medically Necessary," or your state- | spe         | cific required  | d language | to prohibit |  |

PRODUCT SUBSTITUTION PERMITTED/Brand exchange permitted (date)

DISPENSE AS WRITTEN/Do Not Substitute

(date)

Confidentiality Statement: This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain provided, confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately at the address and telephone number set forth herein and obtain instructions as to proper destruction of the transmitted material. Thank you.